Hamanishi et al172 revealed the merits of nivolumab, a PD-1 inhibitor, in cisplatin-resistant ovarian cancer, showing that the median progression-free survival was 3.5 months (95% CI, 1.7–3.9 months) and median overall survival was 20.0 months. This evidence concerns the gene PDCD1 and ovarian cancer.